GDTC
CytoMed Therapeutics Limited
There isn't enough reported data to score GDTC yet.
GDTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
GDTC's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
GDTC PE Valuation
GDTC has no meaningful PE right now: it lost money over the past year.
GDTC Forward outlook
There aren't enough analyst estimates for GDTC to show an outlook.
GDTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.26 | -$0.09 |
| Q4 2024 | -$0.17 | +$0.30 |
| Q4 2023 | -$0.47 | -$0.01 |
| Q3 2023 | -$0.53 | -$0.22 |
| Q2 2023 | -$0.57 | -$0.31 |
| Q1 2023 | -$0.50 | -$0.22 |
| Q4 2022 | -$0.46 | -$0.17 |
| Q3 2022 | -$0.31 | +$0.02 |
GDTC is still losing money, but far less than before: $0.26 per share over the past year, against $0.57 at its worst in mid-2023.
GDTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $252.7K | +367% |
| Q3 2023 | $87.2K | -23% |
| Q1 2023 | $110.5K | +281% |
| Q3 2022 | $112.5K | +239% |
| Q1 2022 | $29K | +161% |
| Q4 2021 | $33.3K | +43% |
| Q3 2021 | $33.2K | +43% |
GDTC's revenue is growing: $252,677 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -1232% | N/A |
| Q4 2024 | -3629% | -2914 points |
| Q3 2023 | -391% | -132 points |
| Q1 2023 | -714% | +133 points |
| Q3 2022 | -259% | +422 points |
| Q1 2022 | -847% | +1156 points |
| Q4 2021 | -2504% | -1313 points |
| Q3 2021 | -681% | +466 points |
GDTC's operating margin was −1232% last quarter, down 973 points from the same quarter a year ago.
GDTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.4M | -$175.4K |
| Q4 2024 | -$3.2M | -$2.6M |
| Q4 2023 | -$601.1K | +$146K |
| Q3 2023 | -$600.3K | -$224.9K |
| Q2 2023 | -$799.5K | -$445.5K |
| Q1 2023 | -$797.3K | -$444K |
| Q4 2022 | -$747.1K | -$103.3K |
| Q3 2022 | -$375.4K | +$267K |
GDTC has burned cash in almost every quarter: −$8M over the past year, against −$3M the year before.
GDTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +107K shares |
| 1 year | +20% | +1.9M shares |
| 3 years | +68% | +4.7M shares |
GDTC has 12M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
GDTC Net Leverage
GDTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GDTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 42.8 | Neutral |
GDTC's weekly RSI is 42 (neutral) and its Stochastic is 43 (neutral).
GDTC PE vs Healthcare Sector
GDTC has no meaningful PE right now: it lost money over the past year.
GDTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.90 | 6.7% below |
| 20 week MA | $0.92 | 8.7% below |
| 50 week MA | $1.05 | 20% below |
| 100 week MA | $1.67 | 50% below |
GDTC is in a downtrend: it's below all four of its weekly moving averages, and 50% below its 100-week average.
GDTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $4.00 | $4.90 | +23% |
| 2024 | $4.90 | $2.89 | -41% |
| 2025 | $2.89 | $1.53 | -47% |
| 2026 YTD | $1.53 | $0.84 | -45% |
GDTC has finished lower in two of the last three years. It's down 45% so far in 2026.